Regeneron Pharmaceuticals said on May 19 that it is buying the bankrupt 23andMe company, which has collected an enormous amount of genetic data.
Regeneron said in a statement that it is purchasing specifically 23andMe’s Personal Genome Service, which has collected the DNA from millions, for a price, as well as other assets. Regeneron won a bankruptcy auction with a $256 million bid.
“We have deep experience with large-scale data management, having worked with collaborators around the world to link deidentified DNA sequences from nearly three million consented participants to electronic health records, safely and securely enabling future medical advances,” Dr. George D. Yancopoulos, president and chief scientific officer of Regeneron, and one of its co-founders, said in a statement….